Xintela AB (SE:XINT)
:XINT
Top Page
Xintela AB
(XINT)
Select Model
Select Model
Rating:41Neutral
Price Target:
kr0.20
▼(-27.86% Downside)
Action:ReiteratedDate:03/03/26
The score is primarily constrained by weak financial performance—persistent losses, significant cash burn, and negative equity—indicating high reliance on external funding. Technicals also lean bearish with price below key moving averages and negative MACD, while valuation is not supportive due to negative earnings and no dividend yield.
Positive Factors
Zero debt / low leverage
Zero reported debt materially reduces near-term refinancing risk for an early-stage biotech that burns cash. This structural low-leverage position preserves optionality for equity financing or partnerships and lowers fixed finance costs, supporting runway management and strategic flexibility.
Negative Factors
Consistent heavy operating cash burn
Sustained large negative operating cash flow creates ongoing dependence on external capital and elevates dilution and execution risk. Over time, persistent burn without clear breakeven trends constrains R&D continuity and commercialization plans absent new financing or major partnerships.
Read all positive and negative factors
Positive Factors
Negative Factors
Zero debt / low leverage
Zero reported debt materially reduces near-term refinancing risk for an early-stage biotech that burns cash. This structural low-leverage position preserves optionality for equity financing or partnerships and lowers fixed finance costs, supporting runway management and strategic flexibility.
Read all positive factors
Xintela AB (XINT) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr203.26M
Dividend YieldN/A
Average Volume (3M)554.92K
Price to Earnings (P/E)―
Beta (1Y)0.73
Revenue Growth-7.68%
EPS Growth17.93%
CountrySE
Employees21
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.02
Shares Outstanding861,266,850
10 Day Avg. Volume503,836
30 Day Avg. Volume554,918
Financial Highlights & Ratios
PEG Ratio-1.38
Price to Book (P/B)-37.15
Price to Sales (P/S)85.84
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.11
Revenue Forecast (FY)N/A
Xintela AB Business Overview & Revenue Model
Company Description
Xintela AB (publ), a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage and brain tumors. The company develops products based on XINMARK, a patented marker technology that identifies and se...
How the Company Makes Money
null...
Xintela AB Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
28
Negative
Cash Flow
14
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.28M | 4.21M | 78.00K | 0.00 | 0.00 |
| Gross Profit | 1.68M | 4.21M | 78.00K | -3.79M | -3.50M |
| EBITDA | -46.08M | -38.90M | -53.47M | -65.28M | -57.11M |
| Net Income | -48.56M | -39.19M | -54.08M | -66.22M | -58.93M |
Balance Sheet | |||||
| Total Assets | 29.02M | 24.80M | 18.39M | 24.52M | 24.74M |
| Cash, Cash Equivalents and Short-Term Investments | 23.21M | 16.68M | 7.81M | 8.34M | 9.94M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 34.30M | 30.75M | 14.02M | 18.74M | 20.80M |
| Stockholders Equity | -5.27M | -5.95M | 4.38M | 5.78M | 3.95M |
Cash Flow | |||||
| Free Cash Flow | 0.00 | -40.70M | -53.22M | -39.60M | -44.15M |
| Operating Cash Flow | -41.62M | -40.70M | -53.12M | -39.49M | -42.89M |
| Investing Cash Flow | 0.00 | 0.00 | -104.00K | -27.52M | -1.20M |
| Financing Cash Flow | 48.53M | 50.09M | 51.79M | 64.56M | 20.43M |
Xintela AB Technical Analysis
Neutral
0.28
Price Trends
0.27
Negative
0.28
Negative
0.34
Negative
Market Momentum
-0.01
Positive
45.99
Neutral
30.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:XINT, the sentiment is Neutral. The current price of 0.28 is above the 20-day moving average (MA) of 0.24, above the 50-day MA of 0.27, and below the 200-day MA of 0.34, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 45.99 is Neutral, neither overbought nor oversold. The STOCH value of 30.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:XINT.
Xintela AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | kr185.11M | -3.65 | -51.35% | ― | ― | -34.02% | |
48 Neutral | kr275.20M | -13.67 | -59.78% | ― | ― | 52.96% | |
45 Neutral | kr117.04M | -1.66 | -1291.15% | ― | ― | 28.54% | |
43 Neutral | kr131.65M | -1.72 | -199.86% | ― | 69.03% | 23.10% | |
43 Neutral | kr39.16M | -1.03 | -457.91% | ― | ― | -19.35% | |
41 Neutral | kr203.26M | -4.03 | ― | ― | -7.68% | 17.93% |
* Healthcare Sector Average
SE:XINT
Xintela AB
0.24
-0.25
-51.14%
SE:ISOFOL
Isofol Medical AB
0.66
-1.08
-62.16%
SE:ELIC
Elicera Therapeutics AB
5.67
3.34
143.35%
SE:IRLAB.A
IRLAB Therapeutics AB Class A
1.55
-4.70
-75.20%
SE:MODTX
Modus Therapeutics Holding AB
0.32
-0.17
-34.55%
SE:ACTI
Active Biotech AB
0.04
-0.03
-41.33%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.